Earnings Preview: Fulgent Genetics

Fulgent Genetics (NASDAQ:FLGT) is preparing to release its quarterly earnings on Friday, 2026-02-27. Here's a brief overview of what investors should keep in mind before the announcement.

Analysts expect Fulgent Genetics to report an earnings per share (EPS) of $-0.09.

The market awaits Fulgent Genetics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.

It's important for new investors to understand that guidance can be a significant driver of stock prices.

Earnings History Snapshot

Last quarter the company beat EPS by $0.50, which was followed by a 0.0% drop in the share price the next day.

Here's a look at Fulgent Genetics's past performance and the resulting price change:

Quarter	Q3 2025	Q2 2025	Q1 2025	Q4 2024
EPS Estimate	-0.36	-0.33	-0.18	-0.12
EPS Actual	0.14	0.07	0.04	0.04
Price Change %	18.15	7.86	19.07	-1.53

Tracking Fulgent Genetics's Stock Performance

Shares of Fulgent Genetics were trading at $23.56 as of February 25. Over the last 52-week period, shares are up 53.46%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

Get to Know Fulgent Genetics Better

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Key Indicators: Fulgent Genetics's Financial Health

Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.

Revenue Growth: Fulgent Genetics's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately 17.18%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Fulgent Genetics's net margin is impressive, surpassing industry averages. With a net margin of -7.86%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Fulgent Genetics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.59% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): Fulgent Genetics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.55%, the company may face hurdles in achieving optimal financial performance.

Debt Management: With a below-average debt-to-equity ratio of 0.01, Fulgent Genetics adopts a prudent financial strategy, indicating a balanced approach to debt management.

To track all earnings releases for Fulgent Genetics visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.